Organogenesis Holdings Inc.
NASDAQ:ORGODrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $110.75M
- Beta
- 1.33
- P/E (TTM)
- -1086.7
- EPS (TTM)
- -$0.00
Volume 0.86M
Average 1.49M
ORGO Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
Organogenesis Holdings Inc.NASDAQ: ORGO
Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026
Income tax expense remains negative
Q1 FY2026 income tax expense was -$12.31M, compared with -$6.94M a year earlier. Trailing-twelve-month income tax expense was $4.56M. Over 3 fiscal years it compounded at +27.9% a year.
Context
- Income tax expense amounted to 1.8% of revenue in FY2025, up 1.0 pp from a year earlier.
- Income tax expense increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income tax expense holds near -$12.31M or moves back toward the trailing-twelve-month quarterly average of $1.14M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 9.94M USD
- Year-over-year change
- +370.9%
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.94M | +370.9% |
| FY2024 | 2024-12-31 | (3.67M) | -167.3% |
| FY2023 | 2023-12-31 | 5.45M | +14.7% |
| FY2022 | 2022-12-31 | 4.75M | +115.3% |
| FY2021 | 2021-12-31 | (31.12M) | — |
Income Tax Expense vs competitors
How ORGO compares with its peers on the latest reported figures
- Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +154.6% is the highest of 8, against a peer median of +25.0%.
- Income tax expense amounts to 0.9% of revenue for ORGO, versus a peer median of 0.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.1M USD | -82.5% | — | 1.8% | |
| LTM Apr 2026 | $7.4M USD | -87.2% | -7.9% | 0.9% | |
| LTM Mar 2026 | $6.67M USD | -51.5% | -11.5% | 7.1% | |
| LTM Mar 2026 | $4.56M USD | +154.6% | +27.9% | 0.9% | |
| LTM Mar 2026 | $1.84M USD | — | — | 0.4% | |
| LTM Mar 2026 | $1.41M USD | +125.6% | — | 2.2% | |
| LTM Mar 2026 | $861K USD | +25.0% | +92.4% | 0.3% | |
| LTM Feb 2026 | $12K USD | +101.8% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | -CA$1.5M CAD | +76.6% | — | 0.2% | |
| Peer median (excluding ORGO) | — | +25.0% | -7.9% | 0.7% | |
Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 467.36M | 450.89M | 433.14M | 482.04M | 563.03M |
| Cost of Revenue | 114.2M | 105.02M | 106.48M | 115.74M | 137.52M |
| Gross Profit | 353.16M | 345.87M | 326.66M | 366.3M | 425.51M |
| Gross Margin | 75.6% | 76.7% | 75.4% | 76.0% | 75.6% |
| Research & Development | 30.74M | 39.76M | 44.38M | 50.27M | 44.54M |
| Selling, General & Admin | 250.2M | 283.81M | 269.75M | 294.51M | 326.24M |
| Operating Expenses | 280.94M | 323.57M | 314.13M | 367.59M | 369.64M |
| Depreciation & Amortization | 16.68M | 18.03M | 23.45M | 17.03M | 26.94M |
| EBITDA | 87M | 40.32M | 36.03M | 15.76M | 73.91M |
| EBITDA Margin | 18.6% | 8.9% | 8.3% | 3.3% | 13.1% |
| Operating Income | 72.22M | 22.3M | 12.53M | (1.28M) | 55.87M |
| Operating Margin | 15.5% | 4.9% | 2.9% | -0.3% | 9.9% |
| Interest Income | 0 | 0 | 0 | 0 | 2.28M |
| Interest Expense | 7.24M | 2.01M | 2.19M | 1.54M | 0 |
| Other Income / Expenses | (9.13M) | (2.02M) | (2.13M) | (1.52M) | (8.9M) |
| Income Before Tax | 63.09M | 20.28M | 10.39M | (2.81M) | 46.97M |
| Pre-Tax Margin | 13.5% | 4.5% | 2.4% | -0.6% | 8.3% |
| Income Tax Expense | (31.12M) | 4.75M | 5.45M | (3.67M) | 9.94M |
| Net Income | 94.2M | 15.53M | 4.95M | 861K | 37.03M |
| Net Margin | 20.2% | 3.4% | 1.1% | 0.2% | 6.6% |
| EPS (Basic) | 0.73 | 0.12 | 0.04 | (0.01) | 0.16 |
| EPS (Diluted) | 0.70 | 0.12 | 0.04 | (0.01) | 0.15 |
| Weighted Avg Shares | 128.33M | 130.07M | 131.23M | 131.67M | 126.74M |
| Weighted Avg Shares (Diluted) | 133.66M | 132.38M | 132.75M | 131.67M | 130.25M |
Organogenesis Holdings Inc.
NASDAQ:ORGO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.